Literature DB >> 23336859

Treatment of symptomatic isolated dissection of superior mesenteric artery.

Zhihui Dong1, Weiguo Fu, Bin Chen, Daqiao Guo, Xin Xu, Yuqi Wang.   

Abstract

OBJECTIVE: To present the short- to midterm outcomes after management of 14 patients with symptomatic isolated dissection of superior mesenteric artery (SIDSMA) and propose a preliminary treatment algorithm.
BACKGROUND: SIDSMA is a rare but potentially fatal entity. However, most of these reports were isolated case reports, and a consensus treatment protocol remains lacking so far. It would be meaningful to propose a reasonable treatment algorithm for it.
METHODS: Patients with SIDSMA who were treated in our center between July 2007 and June 2011 were retrospectively collected and analyzed. Based upon the abdominal pain and signs, the clinical manifestations have been retrospectively classified into grade I (peritonitis absent) and grade II (peritonitis present). Medical treatment mainly included anticoagulation, antiplatelet, and bowel rest. Endovascular stent placement and surgical fenestration with exploratory laparotomy have been selected according to the grade classification. Computed tomographic angiography, magnetic resonance angiography, or duplex scans have been used for diagnosis and follow-up.
RESULTS: Fourteen consecutive patients with SIDSMA were collected; among them, 13 cases belonged to grade I and one to grade II. The mean duration from the onset to the admission was 12 ± 12 days (range, 0.5-45 days). The mean distance from the primary tear to the ostium of superior mesenteric artery (SMA) was 26 ± 4 mm (range, 15-32 mm). Medical treatment was given for 13 patients of grade I for the first 3 to 5 days after admission, and the abdominal pain remarkably or completely resolved in four patients who received continued medical treatment, whereas the other unresolved nine patients were converted to endovascular stent placement that succeeded in four and failed in five patients. Since these five cases were free from peritoneal signs, medical treatment was given again instead of an immediate surgical intervention, and ultimately achieved complete alleviation of abdominal pain within the following 1 week. The mean duration from the start of medical treatment to the alleviation of symptoms, including the continued medical treatment after the failed endovascular stent placement, was 8 ± 3 days (range, 4-12 days). The grade II patient underwent a successful emergency surgical SMA fenestration without bowel resection. Follow-up was accomplished in all 14 cases, ranging from 2 to 48 months (mean, 30 ± 15 months). No intestinal necrosis, morbidity, or mortality developed during hospitalization. During the follow-up, all patients were free from aneurysmal formation of SMA or chronic intestinal ischemia, and all stents remained patent.
CONCLUSIONS: For grade I SIDSMA, most cases might be successfully treated with medical therapy, and the endovascular stent placement appears to be an acceptable alternative if medical treatment fails. For grade II SIDSMA, the endovascular stenting combined with laparoscopic exploration and/or open surgery could be a reasonable option.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23336859     DOI: 10.1016/j.jvs.2012.07.060

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  13 in total

1.  Comment on "clinical course and angiographic changes of spontaneous isolated superior mesenteric artery dissection after conservative treatment".

Authors:  Zhongzhi Jia; Feng Tian; Guomin Jiang
Journal:  Surg Today       Date:  2014-08-13       Impact factor: 2.549

Review 2.  Isolated dissection of the superior mesenteric artery treated using open emergency surgery.

Authors:  Markus Udo Wagenhäuser; Tolga Atilla Sagban; Mareike Witte; Mansur Duran; Hubert Schelzig; Alexander Oberhuber
Journal:  World J Emerg Surg       Date:  2014-08-14       Impact factor: 5.469

3.  Clinical Outcomes of Anticoagulation Therapy in Patients With Symptomatic Spontaneous Isolated Dissection of the Superior Mesenteric Artery.

Authors:  Youngjin Han; Yong-Pil Cho; Gi-Young Ko; Dong Wan Seo; Min-Ju Kim; Hyunwook Kwon; Hyangkyoung Kim; Tae-Won Kwon
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 4.  Endovascular stenting of spontaneous isolated dissection of the superior mesenteric artery: A case report and literature review.

Authors:  Dong-Na Gao; Qing-Hui Qi; Ping Gong
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

5.  Conservative Management of Spontaneous Isolated Dissection of the Superior Mesenteric Artery.

Authors:  Jae Hyun Kwon; Yoon Hee Han; Jun Kyu Lee
Journal:  Gastroenterol Res Pract       Date:  2017-07-16       Impact factor: 2.260

6.  Transient ischemic jejunitis due to symptomatic isolated superior mesenteric artery dissection: case report and review of literature.

Authors:  Mihaela Mocan; Ionuţ Isaia Jeican; Mihai Moale; Romeo Chira
Journal:  Clujul Med       Date:  2017-01-15

7.  Clinical course of conservative management for isolated superior mesenteric arterial dissection.

Authors:  Sho Sosogi; Ryu Sato; Reona Wada; Hiroya Saito; Shuhei Takauji; Jun Sakamoto; Keisuke Kimura; Hidenori Karasaki; Yusuke Mizukami; Tomoyuki Ohta
Journal:  Eur J Radiol Open       Date:  2019-05-24

8.  Endovascular treatment of a case presented as isolated superior mesenteric artery dissection.

Authors:  Süha Akpınar; Güliz Yılmaz; Nail Bulakbaşı
Journal:  Saudi Med J       Date:  2016-09       Impact factor: 1.484

Review 9.  Current Understandings of Spontaneous Isolated Superior Mesenteric Artery Dissection.

Authors:  Young-Wook Kim
Journal:  Vasc Specialist Int       Date:  2016-06-30

10.  Initial and Middle-Term Outcome of Treatment for Spontaneous Isolated Dissection of Superior Mesenteric Artery.

Authors:  Zilun Li; Huanyu Ding; Zhen Shan; Jianliang Du; Chen Yao; Guangqi Chang; Shenming Wang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.